GPHL ranked 160th among 2019 China Top 500 Enterprises
2019-09-12 16:09:08 GPHL GPHL
The 2019 China Top 500 Enterprises Summit was held in Jinan, Shandong from August 31st to September 1st. On the 2019 list of China’s top 500 enterprises published at the Summit, GPHL ranked 160th with an annual revenue of 116.01 billion RMB, up 5 places from last year. On the list of 2019 China Top 500 Enterprises in Manufacturing Sector, GPHL ranked 64th, up 4 spots from last year. The list is an indicator of the performance of Chinese enterprises that has been published for 15 consecutive years now.
In 2018 GPHL achieved sales revenues of 116.01 billion RMB and a total profit of 5 billion RMB, up 13.65% and 50% respectively on a year-over-year basis. In the first half of 2019, GPHL continued its high quality growth, and reported actual sales income of 65.68 billion RMB and actual total profits of 3.61 billion RMB, with a year-on-year growth of 12% and 39.42% respectively. Its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. reported revenue of 33.34 billion RMB and total profit of 3.212 billion RMB in the first half of 2019, with a year-on-year growth of 124.67% and 6.66% respectively.
‘1828 Wanglaoji’ fresh brewed herbal tea store
Wanglaoji announced Lay Zhang and Zhou Dongyu as its brand endorsers in 2019.
GPHL’s first overseas herbal tea museum was opened in New York in 2018.
Wanglaoji herbal tea museum project was launched in Tokyo in 2019.
On the list of China’s Top 100 Pharmaceutical Companies published in July, GPHL ranked first, claiming the top spot for eight consecutive years now. According to the Notice on Adjustment in the part of the List of Top 100 Central State-owned Enterprises and Top 100 Local State-owned Enterprises, GPHL was a newly listed company, making it one of the two Guangdong enterprises to take on a pioneering role in the new wave of state-owned enterprise reform.
Wanglaoji’s new product Ci Ning Ji was launched in the first half of 2019.
GPHL’s Chinese patent medicine
GPHL’s cephalosporin compound was granted a United States patent.
GPHL appointed Nobel laureate Randy Schekman as the chief scientist of both the group and Guangzhou General Pharmaceutical Research Institute Co., Ltd.
In recent years, GPHL has been promoting TCM in a more fashionable way, using the most advanced technology and marketing strategies that are most welcomed by the masses, and bringing China Time-honored Brands back to life.
GPHL entered into an agreement with Yixintang.
GPHL becomes the presenting partner for the Fortune Global Tech Forum 2019.
Author: Michelle Wang
Editors: Monica Liu, Simon Haywood